Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nu-Med PlusNUMD EV-to-EBIT is -34.60 as of Jul. 22, 2026. The stock has 1 warning sign investors should review. Among 465 Medical Devices & Instruments companies, Nu-Med Plus ranks worse than 215053.55% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Nu-Med Plus's Enterprise Value for the quarter that ended in Mar. 2026 was $1.14 Mil.
Nu-Med Plus's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nu-Med Plus EV-to-EBIT Related Terms
Nu-Med Plus EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Nu-Med Plus's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nu-Med Plus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nu-Med Plus EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nu-Med Plus's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Nu-Med Plus's EV-to-EBIT falls into.
Nu-Med Plus's current Enterprise Value is $1.49 Mil.
Nu-Med Plus's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nu-Med Plus (NUMD) has a EV-to-EBIT of -34.60 as of Jul. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nu-Med Plus and its competitors. According to the industry distribution chart, Nu-Med Plus ranks #999999 out of 465 companies in the Medical Devices & Instruments industry.
Is Nu-Med Plus' EV-to-EBIT too high?
Nu-Med Plus' current EV-to-EBIT is -34.60. Based on the distribution chart, Nu-Med Plus ranks #999999 out of 465 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Nu-Med Plus' EV-to-EBIT compare to SSKN and ODYY?
According to the Medical Devices & Instruments industry distribution chart, Nu-Med Plus ranks #999999 out of 465 companies for EV-to-EBIT. This places Nu-Med Plus in the lower half of its industry. The industry median EV-to-EBIT is 18.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.28, based on 465 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Nu-Med Plus and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nu-Med Plus's current EV-to-EBIT is -34.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nu-Med Plus stock overvalued right now?
Nu-Med Plus (NUMD) has a current EV-to-EBIT of -34.60. The current EV-to-EBIT is -34.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Nu-Med Plus (NUMD), the current EV-to-EBIT is -34.60 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nu-Med Plus Inc is a medical device company engaged in the design, innovation, development, enhancement, and commercialization of beginning, early, and selective later-stage quality medical devices. It focuses on the formulation of Nitric Oxide powder, which is a desktop generator device which delivers inhaled Nitric Oxide to replace expensive pressurized canisters and a mobile rechargeable device to deliver inhaled Nitric Oxide gas to offer solutions to hospitals, health systems, and the medical community throughout the world. It is currently working to locate a merger partner that will be able to fund the final development of these products.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NUMD has been successfully added to your 
